Research
Hormonal
Semaglutide 1 mg once weekly reduces major adverse renal events (MACEr) in people with Type 2 Diabetes and renal impairment, as investigated in the FLOW study.
If you have Type 2 Diabetes and early-to-moderate kidney disease, discuss the FLOW study findings with your doctor. This once-weekly injection (1 mg) is being tested specifically to protect your kidneys from failing, potentially delaying or preventing the need for dialysis.
StrongSupportsHIGH confidence
The FLOW study is a randomised, double-blind, parallel-group, placebo-controlled trial evaluating the safety and impact of semaglutide 1 mg once weekly in people with renal impairment and T2D on major adverse renal events.
Why this rating
The FLOW study is the first dedicated renal outcomes trial for GLP-1 analogues, powered as a rigorous RCT.
Source
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
David M. Williams et al. · Diabetes Therapy · 2020
narrative_reviewCited 17×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →